GNVR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-14

• Genvor, through its wholly-owned subsidiary, Genvor Inc., is developing an AI-enabled peptide platform focused on proprietary peptide candidates for agricultural crop protection, crop optimization and related health and wellness applications. The Company’s most advanced scientific foundation is its …

• The Company’s peptide technology has advanced from in vitro testing into transgenic maize greenhouse studies. Peer-reviewed published data showed that the Company’s peptides reduced growth of numerous bacterial and fungal pathogens, and that its lead product candidates, AGM182, GV185 and GV187, redu…

• The Company also intends to use its peptide library and its AI-enabled peptide design platform, BioCypher, to further design, identify, optimize and license peptide candidates to third parties, including potential partners in agriculture and human health and wellness. In human health and wellness, t…

• Over the next four years, the Company intends to focus on researching and developing portfolio solutions for the following:

• ● Insecticides: insecticidal peptides to control key insects and nematodes; and

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• Genvor, through its wholly-owned subsidiary, Genvor Inc., is pioneering the development and commercialization of AI-accelerated peptide technology to address critical challenges across two markets: agricultural biologicals and human health and wellness. Management believes Genvor’s proprietary AI-ac…

• With respect to agriculture, antimicrobial peptides (“AMPs”) are intended to provide broad-spectrum protection against fungal, bacterial, and viral pathogens that threaten crop productivity worldwide while nutritionally enhanced peptides (“NEPs”) are intended to optimize nutrient uptake and utilizat…

• These peptide technologies are distinguished by their multiple modes of action and biodegradability, which are intended to significantly reduce the risk of resistance development that increasingly limits the effectiveness of conventional chemical pesticides. The Company’s solutions are intended to m…

• The Company’s strategic vision extends beyond crop protection to encompass the broader agricultural value chain as Genvor is actively developing applications for its peptide portfolio in animal health and nutrition, where NEPs demonstrate potential to improve feed conversion efficiency, enhance gut …

• Effective April 16, 2026, the Company entered into a securities purchase agreement (the “SPA”) with Evergreen Capital Management LLC (“Evergreen”), pursuant to which the Company sold, and Evergreen purchased, (i) a convertible promissory note in the aggregate principal amount of up to $800,000 (the …

Text added vs the prior filing · source: 10-Q · 2026-08-14

• Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) at June 30, 2026, the end of the period covered by…

• A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

• In connection with the audit of our consolidated financial statements for the year ended September 30, 2025, management identified the following material weaknesses in our internal control over financial reporting, which had not been remediated at June 30, 2026:

• During the quarter ended June 30, 2026, management identified the following additional matters relating to the Company’s tax filing, reporting and withholding obligations, which were determined to be material weaknesses:

• ● Compensation processed through payroll was subject to withholding and reporting. Compensation and other amounts provided to employees in other forms, including amounts deferred, drawn or settled in equity, had not been fully evaluated for their payroll tax and reporting consequences, and the relat…

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• The SEC defines the term “disclosure controls and procedures” to mean a company’s controls and other procedure that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within …

• Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026, the end of the …

• To remediate our internal control weaknesses, management intends to implement the following measures:

• ● The Company intends to add a sufficient number of independent directors to the board and form an audit committee.

• ● The Company intends to add sufficient knowledgeable accounting personnel to properly segregate duties and to affect a timely, accurate preparation of the financial statements.